NO20044698L - Statinterapi for a oke kognitiv opprettholdelse - Google Patents

Statinterapi for a oke kognitiv opprettholdelse

Info

Publication number
NO20044698L
NO20044698L NO20044698A NO20044698A NO20044698L NO 20044698 L NO20044698 L NO 20044698L NO 20044698 A NO20044698 A NO 20044698A NO 20044698 A NO20044698 A NO 20044698A NO 20044698 L NO20044698 L NO 20044698L
Authority
NO
Norway
Prior art keywords
statin
statin therapy
increase cognitive
galantamine
active ingredient
Prior art date
Application number
NO20044698A
Other languages
English (en)
Inventor
Sean Lilienfeld
Elane M Gutterman
Royston John Glasspool
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20044698L publication Critical patent/NO20044698L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører en fremgangsmåte for å behandle demens eller en hukommelsesforstyrrelse omfattende administrasjon av en terapeutisk effektiv mengde av galantamin (I) og et statin (II). Oppfinnelsen vedrører videre produkter inneholdende som første aktive ingrediens galantamin (I) og som andre aktive ingrediens et statin (II), som kombinerte preparater for samtidig, separat eller sekvensiell anvendelse i behandlingen av pasienter som lider av Alzheimers sykdom eller beslektede demenser; relaterte farmasøytiske sammensetninger og anvendelser.
NO20044698A 2002-04-02 2004-10-29 Statinterapi for a oke kognitiv opprettholdelse NO20044698L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (1)

Publication Number Publication Date
NO20044698L true NO20044698L (no) 2004-10-29

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044698A NO20044698L (no) 2002-04-02 2004-10-29 Statinterapi for a oke kognitiv opprettholdelse

Country Status (22)

Country Link
EP (1) EP1492539B1 (no)
JP (1) JP2005525391A (no)
KR (1) KR100986194B1 (no)
CN (1) CN100528164C (no)
AT (1) ATE331523T1 (no)
AU (1) AU2003226753B2 (no)
BR (1) BR0308293A (no)
CA (1) CA2480275C (no)
CY (1) CY1105545T1 (no)
DE (1) DE60306503T2 (no)
DK (1) DK1492539T3 (no)
EA (1) EA013069B1 (no)
ES (1) ES2268393T3 (no)
HK (1) HK1079688A1 (no)
IL (2) IL164317A0 (no)
MX (1) MXPA04009535A (no)
NO (1) NO20044698L (no)
NZ (1) NZ536111A (no)
PL (1) PL211160B1 (no)
PT (1) PT1492539E (no)
UA (1) UA79605C2 (no)
WO (1) WO2003082298A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
JP2007532624A (ja) * 2004-04-14 2007-11-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルツハイマー病の治療のための療法組合せ
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US20160303146A1 (en) * 2013-12-13 2016-10-20 David A. TABACZYNSKI Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Also Published As

Publication number Publication date
MXPA04009535A (es) 2005-01-25
CN100528164C (zh) 2009-08-19
DK1492539T3 (da) 2006-10-30
EP1492539B1 (en) 2006-06-28
IL164317A0 (en) 2005-12-18
AU2003226753B2 (en) 2007-06-28
KR20040096608A (ko) 2004-11-16
NZ536111A (en) 2006-03-31
IL164317A (en) 2010-04-29
ES2268393T3 (es) 2007-03-16
WO2003082298A1 (en) 2003-10-09
PL211160B1 (pl) 2012-04-30
KR100986194B1 (ko) 2010-10-07
JP2005525391A (ja) 2005-08-25
BR0308293A (pt) 2004-12-28
CY1105545T1 (el) 2010-07-28
ATE331523T1 (de) 2006-07-15
DE60306503D1 (de) 2006-08-10
DE60306503T2 (de) 2007-06-21
HK1079688A1 (en) 2006-04-13
EA013069B1 (ru) 2010-02-26
EA200401295A1 (ru) 2005-02-24
CA2480275C (en) 2011-08-16
AU2003226753A1 (en) 2003-10-13
CN1642555A (zh) 2005-07-20
EP1492539A1 (en) 2005-01-05
UA79605C2 (en) 2007-07-10
PL371551A1 (en) 2005-06-27
CA2480275A1 (en) 2003-10-09
PT1492539E (pt) 2006-11-30

Similar Documents

Publication Publication Date Title
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
WO2001054681A8 (en) Composition for treatment of stress
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BG101118A (en) Therapeutical compounds
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE273693T1 (de) Proteinhaltige arzneimittel
ATE231852T1 (de) Bicyclische aromatische verbindungen
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
NO20006337L (no) Diarylselenidforbindelser og deres anvendelse i human- eller veterinærmedisin og i kosmetikk
Lobo et al. Use of Theraflex-TMJ topical cream for the treatment of temporomandibular joint and muscle pain
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
AU2002333535A1 (en) Treatment of excessive radiation (e.g. sunburn) exposure
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
RU94032792A (ru) Применение 5нтiа - антагонистов для прекращения использования табака
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
EP0402208A1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application